Article Information
- Received February 5, 2019
- Revision received May 21, 2019
- Accepted July 3, 2019
- First published July 12, 2019.
- Version of record published August 21, 2019.
Author Information
Author contributions
Author contributions: C.R.B., C.L.P., and L.H.T. designed research; C.R.B., V.R., and W.F.A. performed research; C.R.B., W.F.A., C.L.P., and L.H.T. analyzed data; C.R.B., C.L.P., and L.H.T. wrote the paper; C.L.P. and L.H.T. edited the paper.
↵*C.L.P. and L.H.T. contributed equally to this work.
Disclosures
- Received February 5, 2019.
- Revision received May 21, 2019.
- Accepted July 3, 2019.
This work was supported by the National Health and Medical Research Council (NHMRC Grants 1042584 and 1022637). The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from an Operational Infrastructure Support Grant. C.R.B. is supported by an NHMRC Peter Doherty training fellowship, C.L.P. is an NHMRC Senior Research Fellow. We thank Jason Howitt for technical assistance with PLA Assays, Mong Tien and Jessica Kauhausen for assistance with tissue processing and histology, and Richard Anderson and John Hemperly for provision of the 6096 L1 blocking antibody.
The authors declare no competing financial interests.
- Correspondence should be addressed to Christopher R. Bye at chris.bye{at}florey.edu.au or Lachlan H. Thompson at lachlant{at}unimelb.edu.au
Other Version
- previous version (July 12, 2019).
- You are viewing the most recent version of this article.
